U.S. Markets open in 4 hrs 59 mins
  • S&P Futures

    3,975.00
    +9.25 (+0.23%)
     
  • Dow Futures

    33,834.00
    +31.00 (+0.09%)
     
  • Nasdaq Futures

    11,690.50
    +45.00 (+0.39%)
     
  • Russell 2000 Futures

    1,821.20
    +1.50 (+0.08%)
     
  • Crude Oil

    71.64
    +0.18 (+0.25%)
     
  • Gold

    1,803.30
    +1.80 (+0.10%)
     
  • Silver

    23.24
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0552
    -0.0008 (-0.0739%)
     
  • 10-Yr Bond

    3.4910
    0.0000 (0.00%)
     
  • Vix

    22.57
    -0.11 (-0.49%)
     
  • GBP/USD

    1.2241
    +0.0003 (+0.0257%)
     
  • USD/JPY

    136.3100
    -0.3200 (-0.2342%)
     
  • BTC-USD

    17,221.11
    +396.64 (+2.36%)
     
  • CMC Crypto 200

    406.09
    +11.40 (+2.89%)
     
  • FTSE 100

    7,462.62
    -9.55 (-0.13%)
     
  • Nikkei 225

    27,901.01
    +326.58 (+1.18%)
     

BiondVax to Present at Aegis Virtual Conference

JERUSALEM, Feb. 22, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 23rd at 9:30am ET.

BiondVax Pharmaceuticals Logo
BiondVax Pharmaceuticals Logo

The presentation, which will focus on BiondVax's development of innovative nanosized antibodies (NanoAbs) that exhibit significant competitive advantages over existing therapies, will be available by request to Aegis for the duration of the conference from February 23 through 25, 2022. The slide deck will also be made available on BiondVax's website at https://www.biondvax.com/investors. Further information about the conference is available at https://www.aegiscapcorp.com/2022-aegis-virtual-conference/.

About BiondVax

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, please visit www.biondvax.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding management's participation in investor conferences. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that BiondVax will not execute an additional agreement with the Max Planck Society and the University Medical Center Göttingen or that it will be delayed; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that BiondVax and EIB will not reach agreement with respect to the restructuring of the loan from European Investment Bank; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire rights to additional product opportunities; BiondVax's ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's prospectus supplement filed with the Securities and Exchange Commission on December 28, 2021. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo - https://mma.prnewswire.com/media/615570/BiondVax_Pharmaceuticals_Logo.jpg

Contact Details

Company:
Joshua E. Phillipson
+972 8 930 2529
j.phillipson@biondvax.com

Investor Relations:
Kenny Green
+1-212-378-8040
kgreen@edisongroup.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/biondvax-to-present-at-aegis-virtual-conference-301487403.html

SOURCE BiondVax Pharmaceuticals Ltd.